Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial-Reference-Cited by-同舟云学术

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial

Published:2007-05 Issue:2 Volume:105 Page:358-364
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Kushner David M.,Connor Joseph P.,Sanchez Federico,Volk Michael,Schink Julian C.,Bailey Howard H.,Harris Linda S.,Stewart Sarah L.,Fine Jason,Hartenbach Ellen M.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference50 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J. Clin.,2006

2. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group;Swenerton;J. Clin. Oncol.,1992

3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996

4. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J. Clin. Oncol.,2003

5. Second-line treatment of ovarian cancer;Markman;Oncologist.,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy;Advances in Experimental Medicine and Biology;2024

2. Overview of Ovarian Cancer Chemotherapy;Advances in Diagnosis and Management of Ovarian Cancer;2022

3. Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy;International Journal of Gynecologic Cancer;2015-09

4. Dose-dense Paclitaxel in Advanced Ovarian Cancer;Clinical Oncology;2015-01

5. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer;BMC Cancer;2014-12